When Cuban scientist Dr. Teresita Rodríguez’s mother was diagnosed with Alzheimer’s, she turned heartbreak into innovation—developing and testing a groundbreaking stroke drug on her mother and discovering its potential to slow the progression of Alzheimer’s. Amid the devastating effects of the U.S. embargo on Cuba which has devastated the country’s economy and blocked its biotech industry—a powerhouse in Latin America—Teresita and her all-woman team of scientists race to finalize clinical trials and release the Alzheimer’s drug, NeuroEpo, by 2026.